JP2003514859A5 - - Google Patents

Download PDF

Info

Publication number
JP2003514859A5
JP2003514859A5 JP2001539448A JP2001539448A JP2003514859A5 JP 2003514859 A5 JP2003514859 A5 JP 2003514859A5 JP 2001539448 A JP2001539448 A JP 2001539448A JP 2001539448 A JP2001539448 A JP 2001539448A JP 2003514859 A5 JP2003514859 A5 JP 2003514859A5
Authority
JP
Japan
Prior art keywords
compound
formula
chemical
polymorph
alpha
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2001539448A
Other languages
English (en)
Japanese (ja)
Other versions
JP2003514859A (ja
JP4425514B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2000/032353 external-priority patent/WO2001037833A1/en
Publication of JP2003514859A publication Critical patent/JP2003514859A/ja
Publication of JP2003514859A5 publication Critical patent/JP2003514859A5/ja
Application granted granted Critical
Publication of JP4425514B2 publication Critical patent/JP4425514B2/ja
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

JP2001539448A 1999-11-29 2000-11-27 5−クロロ−3−(4−メタンスルホニルフェニル)−6′−メチル−[2,3′]ビピリジニルの多形型、非晶質型および水和型 Expired - Lifetime JP4425514B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US16792299P 1999-11-29 1999-11-29
US60/167,922 1999-11-29
PCT/US2000/032353 WO2001037833A1 (en) 1999-11-29 2000-11-27 Polymorphic, amorphous and hydrated forms of 5-chloro-3-(4-methanesulfonylphenyl)-6'-methyl-[2,3']bipyridinyl

Publications (3)

Publication Number Publication Date
JP2003514859A JP2003514859A (ja) 2003-04-22
JP2003514859A5 true JP2003514859A5 (cg-RX-API-DMAC7.html) 2005-12-22
JP4425514B2 JP4425514B2 (ja) 2010-03-03

Family

ID=22609368

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2001539448A Expired - Lifetime JP4425514B2 (ja) 1999-11-29 2000-11-27 5−クロロ−3−(4−メタンスルホニルフェニル)−6′−メチル−[2,3′]ビピリジニルの多形型、非晶質型および水和型

Country Status (11)

Country Link
US (3) US6441002B1 (cg-RX-API-DMAC7.html)
EP (1) EP1248618B1 (cg-RX-API-DMAC7.html)
JP (1) JP4425514B2 (cg-RX-API-DMAC7.html)
AT (1) ATE320809T1 (cg-RX-API-DMAC7.html)
AU (1) AU776544B2 (cg-RX-API-DMAC7.html)
CA (1) CA2391650C (cg-RX-API-DMAC7.html)
DE (1) DE60026877T2 (cg-RX-API-DMAC7.html)
DK (1) DK1248618T3 (cg-RX-API-DMAC7.html)
ES (1) ES2259295T3 (cg-RX-API-DMAC7.html)
PT (1) PT1248618E (cg-RX-API-DMAC7.html)
WO (1) WO2001037833A1 (cg-RX-API-DMAC7.html)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PH12001001175B1 (en) * 2000-05-26 2006-08-10 Merck Sharp & Dohme 5-chloro-3-(4-methanesulfonylphenyl)-6'-methyl- (2,3')bipyridinyl in pure crystalline form and process for synthesis
US6521642B2 (en) * 2000-05-26 2003-02-18 Merck & Co., Inc. 5-chloro-3-(4-methanesulfonylphenyl)-6′-methyl-[2,3′]bipyridinyl in pure crystalline form and process for synthesis
WO2005085199A1 (en) * 2004-01-14 2005-09-15 Cadila Healthcare Limited Novel polymorphs of etoricoxib
HUE028730T2 (en) 2009-02-27 2017-01-30 Cadila Healthcare Ltd Process for the preparation of etoricoxib
WO2012163839A1 (en) 2011-05-27 2012-12-06 Farma Grs, D.O.O. A process for the preparation of polymorphic form i of etoricoxib
EP2773618A1 (en) 2011-11-03 2014-09-10 Cadila Healthcare Limited An improved process for the preparation of etoricoxib and polymorphs thereof
WO2013075732A1 (en) 2011-11-21 2013-05-30 Synthon Bv Process for making crystalline form i of etoricoxib
EP2601952A1 (en) 2011-12-07 2013-06-12 Zentiva, k.s. Novel pharmaceutically acceptable salts and cocrystals of 5-chloro-3-(4-methanesulfonylphenyl)-6'-methyl-[2,3']bipyridinyl and their therapeutic uses
EP2831045A2 (en) * 2012-03-30 2015-02-04 Mylan Laboratories, Limited An improved process for the preparation of etoricoxib
WO2014041558A2 (en) 2012-08-27 2014-03-20 Glenmark Pharmaceuticals Limited; Glenmark Generics Limited Process for preparation of crystalline etoricoxib
CN104418799A (zh) * 2013-09-03 2015-03-18 天津药物研究院 一种依托考昔的晶型及其制备方法和应用
WO2015036550A1 (en) 2013-09-13 2015-03-19 Synthon B.V. Process for making etoricoxib
CN107056691B (zh) * 2017-06-21 2020-03-10 四川尚锐生物医药有限公司 一种制备依托考昔晶型v的方法
WO2019130049A1 (en) 2017-12-29 2019-07-04 Grünenthal GmbH Pharmaceutical combination comprising extended-release tramadol hydrochloride and immediate-release etoricoxib, and its use for the treatment of pain
CN111410629A (zh) * 2020-03-31 2020-07-14 天津大学 依托考昔溶剂化物及其制备方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5321033A (en) 1991-11-15 1994-06-14 Merck Frosst Canada, Inc. Amorphous (quinolin-2-ylmethoxy)indole compounds useful for treating inflammatory diseases
SI0912518T1 (en) 1996-07-18 2003-12-31 Merck Frosst Canada & Co. Substituted pyridines as selective cyclooxygenase-2 inhibitors
US5861419A (en) * 1996-07-18 1999-01-19 Merck Frosst Canad, Inc. Substituted pyridines as selective cyclooxygenase-2 inhibitors
US6130334A (en) 1998-04-15 2000-10-10 Merck & Co., Inc. Process for making 2-aryl-3-aryl-5-halo pyridines useful as COX-2 inhibitors
US6127545A (en) 1997-04-18 2000-10-03 Merck & Co., Inc. Process for making 2-aryl-3-aryl-5-halo pyridines useful as COX-2 inhibitors
US6040450A (en) 1997-09-25 2000-03-21 Merck & Co., Inc. Process for making diaryl pyridines useful as cox-2-inhibitors
UA57143C2 (uk) 1998-04-24 2003-06-16 Мерк Енд Ко., Інк. Спосіб синтезу інгібіторів сох-2 (циклооксигенази-2) та проміжні сполуки для їх одержання
PH12001001175B1 (en) * 2000-05-26 2006-08-10 Merck Sharp & Dohme 5-chloro-3-(4-methanesulfonylphenyl)-6'-methyl- (2,3')bipyridinyl in pure crystalline form and process for synthesis
US6521642B2 (en) * 2000-05-26 2003-02-18 Merck & Co., Inc. 5-chloro-3-(4-methanesulfonylphenyl)-6′-methyl-[2,3′]bipyridinyl in pure crystalline form and process for synthesis

Similar Documents

Publication Publication Date Title
JP2005517696A5 (cg-RX-API-DMAC7.html)
JP2005503386A5 (cg-RX-API-DMAC7.html)
JP2010516681A5 (cg-RX-API-DMAC7.html)
CA2410234C (en) 5-chloro-3-(4-methanesulfonylphenyl)-6'-methyl-[2,3']bipyridinyl in pure crystalline form and process for synthesis
TWI310032B (en) Non-steroidal androgen compounds
RU2007110026A (ru) ПОЛИМОРФНЫЕ И АМОРФНАЯ ФОРМЫ ФОСФАТНОЙ СОЛИ 8-ФТОР-2-{4-[(МЕТИЛАМИНО)МЕТИЛ]ФЕНИЛ}-1,3,4,5-ТЕТРАГИДРО-6Н-АЗЕПИНО[5.4.3-cd]ИНДОЛ-6-ОНА
AU2002320822A1 (en) Polymorphic forms of 1-'4-(5-cyanoindol-3-yl)butyl-4-(2-carbamoylbenzofuran-5-yl)piperazine hydrochloride
PL208708B1 (pl) Polimorficzne formy chlorowodorku 1-4-(5-cyjanoindolo-3 -ylo) butylo-4- (2-karbamoilobenzofurano-5-ylo) piperazyny, sposób ich otrzymywania, ich zastosowanie w terapii zaburzeń medycznych i zawierające je kompozycje farmaceutyczne
JP2003516394A5 (cg-RX-API-DMAC7.html)
JP2010539237A5 (cg-RX-API-DMAC7.html)
JP2009521414A5 (cg-RX-API-DMAC7.html)
AU2001264804A1 (en) 5-chloro-3-(4-methanesulfonylphenyl)-6'-methyl- [2,3']bipyridinyl in pure crystalline form and process for synthesis
CA2391650A1 (en) Polymorphic, amorphous and hydrated forms of 5-chloro-3-(4-methanesulfonylphenyl)-6'-methyl-[2,3']bipyridinyl
CA2824307A1 (en) F, g, h, i and k crystal forms of imatinib mesylate
CA2447878C (en) 5-chloro-3-(4-methanesulfonylphenyl)-6'-methyl-[2,3']bipyridinyl in pure crystalline form and process for synthesis
CA2690137A1 (en) Polymorphic and other crystalline forms of cis-ftc
TWI327138B (en) Improved process for the production of nitroguanidine derivative
AU2001292907A1 (en) 5-chloro-3-(4-methanesulfonylphenyl)-6'-methyl-[2,3']bipyridinyl in pure crystalline form and process for synthesis
RU2005105688A (ru) Полиморфизм додекагидроциклопента (а) фенантренилового эфира тиофенкарбоновой кислоты
TW202010499A (zh) 經取代的吡啶酮之三環化合物的製備方法
KR20060080817A (ko) 시부트라민의 디카복실산염
JP2005501857A5 (cg-RX-API-DMAC7.html)
CN106866638A (zh) 一种阿伐那非‑柠檬酸共晶及其制备方法
JP2023522023A5 (cg-RX-API-DMAC7.html)
RU2487128C2 (ru) Соли 3-(1н-индол-3-ил)-4-[2-(4-метилпиперазин-1-ил)хиназолин-4-ил]пиррол-2,5-диона